
🧬 Rafael Rosengarten - Part 3 | Leveraging AI in Precision Medicine | How Predictive Biomarkers Transform Oncology | Lessons from Scaling a Startup
Part 3 of 4: My guest today is Rafael Rosengarten, CEO and Co-Founder of Genialis, the RNA biomarker company. Genialis is reimagining biomarkers for every target, drug, and patient using a combination of precision oncology, RNA, and AI. Rafael, a biomedical research veteran, combines academic excellence with industry innovation. A Dartmouth graduate with a Yale doctorate, he conducted postdoctoral research at Lawrence Berkeley National Laboratory, where he co-invented the j5 DNA assembly tool. As co-founder of the Alliance for AI in Healthcare, he advocates for responsible AI integration in medicine, drawing from his extensive background in evolution, immunology, bioengineering, and genetics.
The Biotech Startups Podcast · Excedr
Audio is streamed directly from the publisher (media.fame.so) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Part 3 of 4: My guest today is Rafael Rosengarten, CEO and Co-Founder of Genialis, the RNA biomarker company. Genialis is reimagining biomarkers for every target, drug, and patient using a combination of precision oncology, RNA, and AI.
- Rafael’s move to Baylor College of Medicine and Houston’s vibrant medical community
- Innovations in molecular cloning and synthetic biology tools at Baylor
- Bridging biology and AI through collaborations with University of Ljubljana researchers
- Founding Genialis and shifting its focus to predictive biomarker development
- Lessons from biotech pivots that shaped Genialis as a leader in precision oncology
Enriched Notes: